Victory Capital Management Inc. Cuts Position in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Posted by on May 23rd, 2023

Victory Capital Management Inc. lessened its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 5.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 142,718 shares of the biopharmaceutical company’s stock after selling 8,264 shares during the quarter. Victory Capital Management Inc. owned 0.06% of Horizon Therapeutics Public worth $15,659,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its holdings in shares of Horizon Therapeutics Public by 6.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,302 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 145 shares in the last quarter. Profund Advisors LLC increased its holdings in shares of Horizon Therapeutics Public by 0.6% in the 4th quarter. Profund Advisors LLC now owns 25,277 shares of the biopharmaceutical company’s stock valued at $2,877,000 after purchasing an additional 156 shares in the last quarter. Quent Capital LLC increased its holdings in Horizon Therapeutics Public by 8.8% during the 3rd quarter. Quent Capital LLC now owns 1,969 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 160 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in Horizon Therapeutics Public by 0.7% during the 4th quarter. Rice Hall James & Associates LLC now owns 23,162 shares of the biopharmaceutical company’s stock valued at $2,636,000 after acquiring an additional 164 shares in the last quarter. Finally, First Republic Investment Management Inc. increased its holdings in Horizon Therapeutics Public by 1.8% during the 2nd quarter. First Republic Investment Management Inc. now owns 10,142 shares of the biopharmaceutical company’s stock valued at $809,000 after acquiring an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 91.01% of the company’s stock.

Horizon Therapeutics Public Stock Performance

Shares of NASDAQ HZNP opened at $100.57 on Tuesday. The company has a market cap of $22.99 billion, a PE ratio of 63.25, a price-to-earnings-growth ratio of 2.99 and a beta of 1.13. Horizon Therapeutics Public Limited has a 12 month low of $57.84 and a 12 month high of $113.83. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.07 and a quick ratio of 3.89. The company has a 50-day simple moving average of $109.07 and a 200-day simple moving average of $105.54.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last released its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.17 by ($0.34). Horizon Therapeutics Public had a return on equity of 20.31% and a net margin of 10.40%. The company had revenue of $832.10 million during the quarter, compared to analyst estimates of $897.06 million. During the same period in the prior year, the business posted $1.34 earnings per share. Horizon Therapeutics Public’s revenue was down 6.0% on a year-over-year basis. On average, equities analysts anticipate that Horizon Therapeutics Public Limited will post 4.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HZNP. StockNews.com began coverage on shares of Horizon Therapeutics Public in a report on Sunday. They set a “buy” rating for the company. TheStreet downgraded shares of Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a report on Monday, May 8th. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $111.42.

Horizon Therapeutics Public Company Profile

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.

Featured Articles

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.